Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial

(2020) Lawrence Blonde et al.   DIABETES OBESITY & METABOLISM

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes

(2020) Ali Muhammed Ali et al.   DIABETES CARE

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

(2019) Bernard Zinman et al.   Lancet Diabetes & Endocrinology

Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes

(2019) Athena Philis-Tsimikas et al.   DIABETES OBESITY & METABOLISM

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

(2019) Thomas A. Zelniker et al.   CIRCULATION

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

(2019) David R Matthews et al.   LANCET

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes

(2019) Yue Zhou et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2019) Søren L Kristensen et al.   Lancet Diabetes & Endocrinology

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETES CARE

Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials

(2019) Dimitrios Patoulias et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis

(2019) Marco Castellana et al.   Scientific Reports

DURATION-8 Randomized Controlled Trial 104-Week Results—Once-Weekly Exenatide (ExQW) plus Once-Daily Dapagliflozin (DAPA) vs. ExQW or DAPA Alone

(2018) SERGE JABBOUR et al.   DIABETES

Effect of Combination Therapy with Liraglutide plus Canagliflozin on HGP and HbA1c vs. Each Therapy Alone in T2DM

(2018) MUHAMMAD ABDUL-GHANI et al.   DIABETES

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study

(2018) Serge A. Jabbour et al.   DIABETES OBESITY & METABOLISM

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial

(2018) Juan P. Frías et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination

(2018) Christophe De Block   Lancet Diabetes & Endocrinology

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

(2018) Bernhard Ludvik et al.   Lancet Diabetes & Endocrinology

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

(2018) Serge A. Jabbour et al.   DIABETES CARE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Methods for including information from multi-arm trials in pairwise meta-analysis

(2017) Gerta Rücker et al.   Research Synthesis Methods

The Cardiovascular Biology of Glucagon-like Peptide-1

(2016) Daniel J. Drucker   Cell Metabolism

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Extracting data from figures with software was faster, with higher interrater reliability than manual extraction

(2016) Antonia Jelicic Kadic et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

(2016) Juan P Frías et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

(2015) G. Fulcher et al.   DIABETES OBESITY & METABOLISM

Canagliflozin (CANA) Added on to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) or Glucagon-like Peptide-1 (GLP-1) Agonists with or Without Other Antihyperglycemic Agents (AHAs) in Type 2 Diabetes Mellitus (T2DM)

(2013) Vincent Woo et al.   Canadian Journal of Diabetes

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal